Xeris Pharmaceuticals News

Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, Vs. Street Est of $41.8M

07:17 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M

MT Newswires19:17

Xeris Biopharma Narrows 2024 View To Rev $175M-$200M >XERS

Xeris Biopharma Narrows 2024 View To Rev $175M-$200M >XERS

Dow Jones19:08

Press Release: Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events Q1 2024 Total Revenue of $40.6M -- up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M

Dow Jones19:01

Xeris Biopharma 1Q Loss $19M >XERS

Xeris Biopharma 1Q Loss $19M >XERS

Dow Jones19:00

Why Are Xeris Biopharma Shares Moving Monday?

Xeris Biopharma Holdings, Inc (NASDAQ:XERS) shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics.What Happened: In a new press

BenzingaMay 6 23:37

Craig-Hallum Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)

TipRanksMay 6 21:07

Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product

Xeris Biopharma Holdings (XERS) said Monday it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a glucagon pro

MT NewswiresMay 6 19:42

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics

For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented

BusinesswireMay 6 19:00

Xeris Biopharma and Beta Bionics Join Forces to Develop Dual-hormone Pump for Diabetes | NASDAQ:XERS

Proactive InvestorsMay 6 17:30

Press Release: Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 Conference call and webcast at 8:30am ET CHICAGO--(BUSINESS WIRE)--May 02, 2024-- Xeris Biopharma Holdings, Inc. (Nasda

Dow JonesMay 2 19:00

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Top Owners Are Retail Investors With 51% Stake, While 45% Is Held by Institutions

Yahoo FinanceApr 5 23:15

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business WireApr 4 04:05

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today

BusinesswireApr 2 19:00

Xeris Gains as Oppenheimer Highlights Drug Technology

Seeking AlphaMar 29 01:11

Xeris Biopharma Initiated at Outperform by Oppenheimer

Xeris Biopharma Initiated at Outperform by Oppenheimer

Dow JonesMar 28 19:02

Oppenheimer Initiates Coverage On Xeris Biopharma Holdings With Outperform Rating, Announces Price Target of $5

Oppenheimer analyst Leland Gershell initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform rating and announces Price Target of $5.

BenzingaMar 28 18:51

ANGI, MLKN and KOD Are Among After Hour Movers

Seeking AlphaMar 28 04:50

Xeris Pharmaceuticals(XERS.US) Director Buys US$9,720 in Common Stocks

$Xeris Pharmaceuticals(XERS.US)$ Director Schmid John P. purchased 4,500 shares of Common Stocks on Mar 14, 2024 at an average price of $2.16 for a total value of $9,720.Source: Announcement What is s

Futu NewsMar 15 09:44

Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)

TipRanksMar 11 12:40

Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results

Yahoo FinanceMar 9 22:14